Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin

Gathings, Robert M.; Orscheln, Courtney S.; Huang, William W.

doi:10.1016/j.jaad.2013.11.032

Cited by 15 publications

(14 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There has been one case report of a patient who was taking vismodegib for BCC and then developed left parietal and left zygomatic squamous cell carcinomas, which were successfully treated with radiotherapy while continuing vismodegib treatment. 4 We are the first, to our knowledge, to report the treatment of BCC using concurrent radiotherapy and vismodegib. Concurrent treatment appeared to be well tolerated and efficacious, with both patients having no evidence of progressive disease at last follow-up, despite discontinuing vismodegib treatment because of adverse effects and not using any subsequent therapy.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

“…Only one case of radiotherapy with vismodegib has previously been reported for the treatment of squamous cell carcinoma. 4 We report the treatment of 2 cases of recurrent head and neck BCC using this novel combination of vismodegib and concurrent radiotherapy.…”

mentioning

confidence: 99%

Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The situation is hampered by the fact that in Poland there are no other therapeutic options available for these patients. The authors of this article await the upcoming results of efficacy and safety of vismodegib in combination with radiotherapy or surgical treatment in adjuvant and neoadjuvant therapy [16,17].…”

Section: Discussionmentioning

confidence: 99%

Vismodegib in the treatment of basal cell carcinoma — Polish clinical experience in the frame of therapeutic program

et al. 2019

View full text Add to dashboard Cite

Introduction. Vismodegib is a small-molecule inhibitor of the sonic hedgehog pathway, registered for the treatment of patients with metastatic or locally advanced basal cell carcinoma, who were disqualified from surgical excision or radiotherapy. The full treatment refund from the National Health Fund has been available in Poland since 1 st January 2018. The aim of the study was to analyse the frequency of occurrence of adverse events based on CTCAE and the treatment results based on the RECIST 1.1 criteria, in a group of patients treated for six or 12 months with vismodegib. Material and methods. The patient database was gathered from three sites and consisted of 42 patients, who represented 53.8% of the patients treated with vismodegib in Poland. The duration of the treatment ranged between three weeks and 68 months. The median of the treatment period was 8.25 months (0.75-68); the median of the observation of patients treated for less than 12 months was eight months (6-11), and for those treated for more than 12 months it was 14 months (12-68). Results. The summary of the treatment results after six and 12 months was performed on 29/42 and 17/42 patients accordingly. Complete response was achieved in 3/29 (10.3%) and 3/16 (17.6%) patients after six and 12 months of treatment, respectively, partial response in 13/29 (44.8%) and 5/16 (29.4%) patients, respectively, and stable disease in 13/29 (44.8%) and 8/16 (50.0%) patients, respectively. Progression of the disease was experienced by 7/42 (16.6%) patients within the period of 3-28 months of treatment. One patient with brain metastases died due to the progression of the disease. Adverse events were reported in 31/42 (73.8%) patients, more than one adverse event in a single patient was reported in 22/42 (52.3%) patients. No serious adverse events were observed.

show abstract

“…Die Einführung der zielgerichteten Therapie des BCC stellt einen der größten Erfolge der translationalen Medizin dar. Durch den Antikörper Vismodegib wird bei lokal fortgeschrittenen oder metastasierten BCC der Hedgehog-Signalweg inhibiert [8,9]. Die Zulassungsstudie dieses Hedgehoginhibitors zeigte bei 63 inoperab len fortgeschrittenen BCC in über 40 % der Fälle ein Therapieansprechen, während bei 30 % der metastasierten BCCPatienten eine Remission zu verzeichnen war.…”

unclassified

“…Auch für SCC der Lippenregion wird mit ca. 8 [12]. Malignant tumors of the skin had been a rare entity 2 decades ago.…”

unclassified

Aktueller Stand der chirurgischen und adjuvanten Therapie der Malignome der Gesichtshaut und der Ohrmuschel

et al. 2015

View full text Add to dashboard Cite

Malignant tumors of the skin had been a rare entity 2 decades ago. Today they are spread rapidly worldwide. Malignant neoplasms of the skin, the largest human organ, may occur from all structures and layers. While previously skin cancer -occurred mainly after the age of 60, the incidence increases now in younger ages. Strong sunburns in the childhood and before the age of 20 are important risk factors for the development of malignancies of the skin. An increased exposure to UV rays is found especially in the facial skin, where basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Merkel cell carcinomas are the most common malignancies. Early diagnosis of malignancies and therapy-oriented mostly surgical approaches are crucial for the prognosis of all skin cancers. Therefore under the aspect of the increasing incidence these topics will be pointed out according to the latest findings including current multimodal therapy concepts and future treatment options.

show abstract

Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin

Cited by 15 publications

References 3 publications

Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma

Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma

Vismodegib in the treatment of basal cell carcinoma — Polish clinical experience in the frame of therapeutic program

Aktueller Stand der chirurgischen und adjuvanten Therapie der Malignome der Gesichtshaut und der Ohrmuschel

Contact Info

Product

Resources

About